At the time of writing, Syndax Pharmaceuticals Inc [SNDX] stock is trading at $10.65, up 0.76%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SNDX shares have gain 14.76% over the last week, with a monthly amount drifted -17.57%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Syndax Pharmaceuticals Inc [NASDAQ: SNDX] stock has seen the most recent analyst activity on October 24, 2024, when UBS initiated its Buy rating and assigned the stock a price target of $37. Previously, Jefferies started tracking the stock with Buy rating on June 28, 2024, and set its price target to $37. On January 31, 2024, downgrade downgraded it’s rating to Sector Perform and revised its price target to $23 on the stock. Mizuho started tracking the stock assigning a Buy rating and suggested a price target of $45 on December 22, 2023. BofA Securities initiated its recommendation with a Buy and recommended $29 as its price target on October 25, 2023. Goldman started tracking with a Buy rating for this stock on October 11, 2023, and assigned it a price target of $30. In a note dated July 27, 2023, Scotiabank initiated an Sector Outperform rating.
For the past year, the stock price of Syndax Pharmaceuticals Inc fluctuated between $8.58 and $25.07. Currently, Wall Street analysts expect the stock to reach $34.3 within the next 12 months. Syndax Pharmaceuticals Inc [NASDAQ: SNDX] shares were valued at $10.65 at the most recent close of the market. An investor can expect a potential return of 222.07% based on the average SNDX price forecast.
Analyzing the SNDX fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -7.87%, Pretax Profit Margin comes in at -7.58%, and Net Profit Margin reading is -7.58%. To continue investigating profitability, this company’s Return on Assets is posted at -0.52, Equity is -1.02 and Total Capital is -0.63.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Syndax Pharmaceuticals Inc [NASDAQ:SNDX] has a current ratio of 5.80. In addition, the Quick Ratio stands at 5.75 and the Cash Ratio stands at 1.63. Considering the valuation of this stock, the price to sales ratio is 20.96, the price to book ratio is 4.26.
Transactions by insiders
Recent insider trading involved Botwood Nicholas A.J., Head of R&D, CMO, that happened on May 16 ’25 when 11765.0 shares were purchased. Director, Huber Martin H. Jr. completed a deal on May 19 ’25 to buy 5000.0 shares. Meanwhile, Director Katkin Keith bought 10000.0 shares on May 19 ’25.
